We are live on ! Find out more
INMB icon

INmune Bio
INMB

11 hedge funds and large institutions have $1.64M invested in INmune Bio in 2019 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

406% more capital inflows, than outflows

Capital inflows: $45.9K | Capital outflows: $9.07K

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

0.07% more ownership

Funds ownership: 2.54% → 2.62% (+0.07%)

0% more funds holding

Funds holding: 11 → 11 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

Holders
11
Holders Change
–
Holders Change %
0%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Deutsche Bank
Deutsche Bank
Germany
+$22.7K
2
BlackRock
BlackRock
New York
+$12.5K
3
TRUE Private Wealth Advisors
TRUE Private Wealth Advisors
Oregon
+$4.82K
4
Advisory Services Network
Advisory Services Network
Georgia
+$2.41K
5
Bank of America
Bank of America
North Carolina
+$14

Top Sellers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
-$5K
2
UBS Group
UBS Group
Switzerland
-$3.07K
3
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
-$1K

INMB Hedge Fund Activity: Q4 2019 in Review

11 of the 5,094 institutional investors tracked by Wall St. Rank reported a position in INmune Bio (INMB) for Q4 2019, worth a combined $1.64M — up 1% from $1.62M a quarter earlier.

Fund positioning in INMB was balanced in Q4 2019: 3 funds opened new positions, 3 closed out, 3 added to existing stakes and 1 trimmed.

The largest buyer was Deutsche Bank, adding an estimated $22.7K. The largest seller was Victory Capital Management, exiting entirely with an estimated $5K sold.

  • 11 institutional investors held INmune Bio (INMB) as of Q4 2019, unchanged from Q3 2019.
  • Funds reported $1.64M of INmune Bio stock for Q4 2019, up 1% quarter-over-quarter.
  • 3 funds opened new INmune Bio positions in Q4 2019 and 3 closed out, a net change of 0 holders.
  • The largest INmune Bio buyer in Q4 2019 was Deutsche Bank, an estimated $22.7K added.
  • The largest INmune Bio seller in Q4 2019 was Victory Capital Management, an estimated $5K sold.

Based on aggregated 13F filings for Q4 2019.